KR102995415B1 - 미토콘드리아 질환을 표적으로 하는 유사체 - Google Patents

미토콘드리아 질환을 표적으로 하는 유사체

Info

Publication number
KR102995415B1
KR102995415B1 KR1020217018416A KR20217018416A KR102995415B1 KR 102995415 B1 KR102995415 B1 KR 102995415B1 KR 1020217018416 A KR1020217018416 A KR 1020217018416A KR 20217018416 A KR20217018416 A KR 20217018416A KR 102995415 B1 KR102995415 B1 KR 102995415B1
Authority
KR
South Korea
Prior art keywords
compound
ischemia
delete delete
acid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018416A
Other languages
English (en)
Korean (ko)
Other versions
KR20210093958A (ko
Inventor
궈주 정
마크 제이. 밤베르거
이네세 스무크스테
Original Assignee
스텔스 바이오테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스텔스 바이오테라퓨틱스 인코포레이티드 filed Critical 스텔스 바이오테라퓨틱스 인코포레이티드
Publication of KR20210093958A publication Critical patent/KR20210093958A/ko
Application granted granted Critical
Publication of KR102995415B1 publication Critical patent/KR102995415B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217018416A 2018-12-18 2019-11-19 미토콘드리아 질환을 표적으로 하는 유사체 Active KR102995415B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862781156P 2018-12-18 2018-12-18
US62/781,156 2018-12-18
PCT/US2019/062284 WO2020131283A1 (en) 2018-12-18 2019-11-19 Analogs that target mitochondrial diseases

Publications (2)

Publication Number Publication Date
KR20210093958A KR20210093958A (ko) 2021-07-28
KR102995415B1 true KR102995415B1 (ko) 2026-07-23

Family

ID=71101584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217018416A Active KR102995415B1 (ko) 2018-12-18 2019-11-19 미토콘드리아 질환을 표적으로 하는 유사체

Country Status (9)

Country Link
US (2) US12252554B2 (cg-RX-API-DMAC7.html)
EP (1) EP3898653A4 (cg-RX-API-DMAC7.html)
JP (1) JP7606966B2 (cg-RX-API-DMAC7.html)
KR (1) KR102995415B1 (cg-RX-API-DMAC7.html)
CN (1) CN113383005A (cg-RX-API-DMAC7.html)
AU (1) AU2019401254B2 (cg-RX-API-DMAC7.html)
CA (1) CA3123610A1 (cg-RX-API-DMAC7.html)
IL (1) IL284014A (cg-RX-API-DMAC7.html)
WO (1) WO2020131283A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases
US20240197623A1 (en) * 2021-04-07 2024-06-20 Stealth Bio Therapeutics Inc. Silica-based formulations of therapeutic oliogpeptides and peptidomimetics
KR102876070B1 (ko) * 2023-02-08 2025-10-24 웰펩 주식회사 신규 펩티도미메틱을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
WO2026151834A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compounds for use in medical management of subjects with muscular dystrophy
WO2026151846A1 (en) 2025-01-09 2026-07-16 Stealth Biotherapeutics Inc. Compositions for use in the treatment of heart failure, idiopathic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, hypertrophic cardiomyopathy, or hypertensive cardiomyopathy

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
US20110118441A1 (en) 2010-12-14 2011-05-19 Xueyun Gao Synthesis of Highly Fluorescent Peptide-Metallic Nanoclusters as Bio-probes
WO2011116007A1 (en) 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20150010588A1 (en) 2012-02-23 2015-01-08 Cornell University Aromatic-cationic peptides and uses of same
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
CN103249423A (zh) 2010-07-09 2013-08-14 康肽德生物医药技术有限公司 预防或治疗缺血/再灌注损伤之后无复流的方法
EP3108975A1 (en) 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916492A1 (en) 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
CN106459169A (zh) 2014-03-03 2017-02-22 康德生物医疗技术公司 药学上相关的芳香族阳离子肽
WO2015183984A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including tocopherol and uses thereof
WO2016144352A2 (en) 2015-03-11 2016-09-15 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substituted maleimide compounds, variants thereof and methods of using the same
WO2017093897A1 (en) 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
CA3010321A1 (en) 2015-12-31 2017-07-06 Scott Duncan Therapeutic compositions including peptides and uses thereof
US20190276494A1 (en) 2016-05-19 2019-09-12 Stealth Biotherapeutics Corp. Compositions and methods for the prevention and treatment of mitochondrial myopathies
WO2018186404A1 (ja) * 2017-04-03 2018-10-11 出光興産株式会社 有機エレクトロルミネッセンス素子及び電子機器
WO2018223032A1 (en) 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
US20200361987A1 (en) 2017-11-15 2020-11-19 Stealth Biotherapeutics Corp. Deuterated tetrapeptides that target mitochondria
CN113544138B (zh) 2018-12-18 2024-10-29 隐形生物治疗公司 线粒体靶向肽
WO2020131283A1 (en) 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004070054A2 (en) 2003-02-04 2004-08-19 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
WO2011116007A1 (en) 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110118441A1 (en) 2010-12-14 2011-05-19 Xueyun Gao Synthesis of Highly Fluorescent Peptide-Metallic Nanoclusters as Bio-probes
US20150010588A1 (en) 2012-02-23 2015-01-08 Cornell University Aromatic-cationic peptides and uses of same
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides

Also Published As

Publication number Publication date
CN113383005A (zh) 2021-09-10
AU2019401254A1 (en) 2021-06-24
WO2020131283A1 (en) 2020-06-25
EP3898653A1 (en) 2021-10-27
KR20210093958A (ko) 2021-07-28
US20220041654A1 (en) 2022-02-10
AU2019401254B2 (en) 2025-05-01
CA3123610A1 (en) 2020-06-25
US20260008810A1 (en) 2026-01-08
US12252554B2 (en) 2025-03-18
JP7606966B2 (ja) 2024-12-26
EP3898653A4 (en) 2022-08-24
JP2022514241A (ja) 2022-02-10
IL284014A (en) 2021-08-31

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

F13 Ip right granted in full following pre-grant review

Free format text: ST27 STATUS EVENT CODE: A-3-4-F10-F13-REX-PX0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)